TY - JOUR
T1 - Epidemiology of venous thromboembolism in hematological cancers
T2 - The Scandinavian Thrombosis and Cancer (STAC) cohort
AU - Gade, Inger Lise
AU - Brækkan, Sigrid
AU - Næss, Inger Anne
AU - Hansen, John Bjarne
AU - Rosendaal, Frits
AU - Cannegieter, Suzanne
AU - Overvad, Kim
AU - Jensvoll, Hilde
AU - Hammerstrøm, Jens
AU - Gran, Olga Vikhammer
AU - Tjønneland, Anne
AU - Kristensen, Søren Risom
AU - Severinsen, Marianne Tang
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Introduction Venous thromboembolism (VTE) is an important cause of morbidity and mortality in cancer patients, however the risk of VTE differs according to cancer type. Hematological cancers have varying phenotypes. Incidence rates (IR) of VTE in different hematological cancer types have not been investigated in a cancer-exposed subset of the general population. Methods In a population-based cohort, we estimated incidence rates of VTE among patients with six subtypes of hematological cancer and among age and sex matched reference subjects. Results During a mean follow-up of 4.8 years, 30 objectively confirmed first-time symptomatic VTEs occurred among 838 subjects with hematological cancer. The IR of VTE was higher in all types of cancer except for indolent lymphoma but including chronic lymphocytic leukemia compared with reference subjects both during the first year after cancer diagnosis and 1–5 years after diagnosis. IR of VTE for indolent lymphoma was not higher than controls. Conclusion The IRs of VTE were increased in all types of hematological cancer (including chronic lymphocytic leukemia) compared with reference subjects except indolent lymphomas.
AB - Introduction Venous thromboembolism (VTE) is an important cause of morbidity and mortality in cancer patients, however the risk of VTE differs according to cancer type. Hematological cancers have varying phenotypes. Incidence rates (IR) of VTE in different hematological cancer types have not been investigated in a cancer-exposed subset of the general population. Methods In a population-based cohort, we estimated incidence rates of VTE among patients with six subtypes of hematological cancer and among age and sex matched reference subjects. Results During a mean follow-up of 4.8 years, 30 objectively confirmed first-time symptomatic VTEs occurred among 838 subjects with hematological cancer. The IR of VTE was higher in all types of cancer except for indolent lymphoma but including chronic lymphocytic leukemia compared with reference subjects both during the first year after cancer diagnosis and 1–5 years after diagnosis. IR of VTE for indolent lymphoma was not higher than controls. Conclusion The IRs of VTE were increased in all types of hematological cancer (including chronic lymphocytic leukemia) compared with reference subjects except indolent lymphomas.
KW - Epidemiology
KW - Hematologic neoplasm
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85029444981&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2017.09.002
DO - 10.1016/j.thromres.2017.09.002
M3 - Journal article
C2 - 28926801
AN - SCOPUS:85029444981
SN - 0049-3848
VL - 158
SP - 157
EP - 160
JO - Thrombosis Research
JF - Thrombosis Research
ER -